Volume 30, Number 8—August 2024
Dispatch
Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody
, Ayako Sedohara1, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, and Hiroshi Yotsuyanagi
Table 2
Laboratory values over time of a person in Japan with HIV 2 years before changing ART regimen to CAB/RPV and the period while on CAB/RPV, showing HBV reactivation in month 4*
| Category | Time from ART change |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| –2 y | 0 mo | 1 mo | 2 mo | 4 mo | 6 mo | 8 mo | 10 mo | 14 mo | |
| ART regimen |
B/F/TAF |
CAB/ RPV oral |
CAB/RPV injectable |
CAB/RPV |
CAB/RPV |
CAB/RPV |
CAB/RPV |
CAB/RPV |
B/F/TAF |
| Laboratory values | |||||||||
| Anti-HBs, IU/mL† | N/A | 6.57 | 5.65 | 8.78 | 0.20 | 0.20 | 0.00 | 0.13 | 0.00 |
| HBsAg, mIU/mL‡ | 0.00 | 0.00 | 0.00 | 0.00 | 816 | 90,332 | 124,890 | 143,785 | 131,765 |
| Anti-HBe, inhibition %§ | NA | NA | NA | Negative | 6.16 | 31.1 | 54.4 | 56.0 | 55.3 |
| HBeAg, S/CO¶ | NA | NA | NA | Negative | 60.5 | 404 | 680 | 835 | 915 |
| HBV DNA, log copies/mL | ND | NA | NA | NA | 3.9 | NA | NA | NA | 8.2 |
| ALT, U/L | 66 | 25 | 0 | 25 | 103 | 158 | 40 | 32 | 27 |
| Total bilirubin, mg/dL | 0.4 | 0.6 | 0.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.4 |
| HBcrAg, Log U/mL# | NA | NA | Negative | NA | NA | NA | NA | NA | >7.1 |
*ALT, alanine aminotransferase; anti-HBe, hepatitis B e-antibody; anti-HBs, hepatitis B surface antibody; ART, antiretroviral therapy; B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; CAB, cabotegravir; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NA, not applicable; ND, not detected; RPV, rilpivirine. †Cutoff value 10 IU/mL. ‡Cutoff value 10 mIU/mL. §Cutoff value 50% inhibition. ¶Cutoff value 1.0 S/CO. #Cutoff value 3.0 log U/mL.
1These first authors contributed equally to this article.